Compare 8x8 Inc (EGHT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Twist Bioscience Corp — how do they compare? 8x8 Inc trades at $2.11 (market cap $311.98M), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 32.3× 8x8 Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and Twist Bioscience Corp for 27 Days on average.
| EGHT | TWST | |
|---|---|---|
Market Cap | $311.98M | $10.08B |
Volume | 1,639,086 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $2.76 | $205.00 |
52-Week Low | $1.59 | $25.45 |
Typical Hold Time | 16 Days | 27 Days |
Enterprise Value | $578.90M | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.13, down 0.47% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth with $715M in 2025 and positive earnings beats in recent quarters, though profitability remains challenged with a net loss of $27M. Recent news highlights cost-saving customer implementations and AI platform growth, while analyst consensus is mixed with a $19.77 price target representing significant upside potential.
EGHT presents a high-risk, high-reward opportunity with substantial analyst upside but faces execution risks amid competitive pressures. The stock's current valuation at 72x P/E reflects growth expectations, but investors must weigh the company's debt load and margin challenges against its strategic positioning in cloud communications and AI innovation.
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
